About Evox Therapeutics

Evox Therapeutics develops gene editing medicines for severe neurodegenerative diseases using its ExoEdit platform. By pairing CRISPR gene editing with exosomes, the company delivers therapies into the brain, addressing diseases like Huntington's and ALS at their genetic source. This overcomes limitations of existing methods that cannot reach the central nervous system. Lead programmes target genes validated by human genetic data, offering potential to slow or halt disease progression rather than managing symptoms. Patients with genetically driven conditions benefit from treatments designed for safety, efficacy and repeat dosing. Evox combines Oxford and Karolinska science with clinical expertise to advance therapies toward the clinic.